Reina J. The new generation of messenger RNA (mRNA) vaccines against influenza. Enferm Infecc Microbiol Clin (Engl Ed). 2022 Jul 2
Today there are multiple types of flu vaccines. The emergence of nucleic acid technology used in vaccines against SARS-CoV-2 suggests its future application against this infection. Against influenza, two types of vaccines have been developed based on messenger RNA (mRNA): conventional or non-replicative and self-amplifying or replicative (auRNA), both included in lipid nanoparticles. Animal studies carried out with the former have shown their strong capacity to induce Th-1 antibodies and cellular immunity against influenza haemagglutinin (HA) with few side effects. Human trials have shown 87% seroconversion and 100% seroprotection. The auRNA vaccines have obtained similar results in animals but at a concentration 64 times lower than the conventional one. Vaccines based on mRNA platforms meet the WHO requirements for next generation influenza vaccines.
See Also:
Latest articles in those days:
- Evolutionary Events Promoted Polymerase Activity of H13N8 Avian Influenza Virus 12 hours ago
- Cross-Species Transmission Potential of H4 Avian Influenza Viruses in China: Epidemiological and Evolutionary Study 12 hours ago
- Wild Bird-Origin H6N2 Influenza Virus Acquires Enhanced Pathogenicity after Single Passage in Mice 12 hours ago
- Genetics of H5N1 and H5N8 High-Pathogenicity Avian Influenza Viruses Isolated in Japan in Winter 2021-2022 12 hours ago
- Avian H6 Influenza Viruses in Vietnamese Live Bird Markets during 2018-2021 12 hours ago
[Go Top] [Close Window]